SecBot SecBot
PRESS-RELEASE ·Filed Sep 10, 2026

SEPN

Septerna, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago WireGlobeNewswire
Press release · Activist
Actionable Insight • Neutral

Routine executive hiring inducement with no immediate trading catalyst. Monitor for future pipeline updates or clinical data releases, which are the primary drivers for this pre-revenue biotech.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$38.51
T+0 close · Sep 10, 2026 · via day close
Latest settled
−0.36%
T+20 · $38.37 · next T+60 in 20d
Vs SPY
−2.23%
α at T+20
Latest observation
+20.44%
T+44 · FF3 residual α
  1. T+0 · Sep 11 $38.51entry
  2. T+1 · 2mo ago +2.70%α +3.15% · $39.55
  3. T+5 · 2mo ago +0.47%α +0.69% · $38.69
  4. T+20 · 6w ago −0.36%α −2.23% · $38.37
  5. T+46 · todayOpen
  6. T+60 · in 20d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Septerna granted a 275,000-share non-qualified stock option inducement award to newly appointed CMO Rajiv Patni under the 2026 Inducement Plan, effective September 8, 2026. This is a routine hiring inducement for a biotech executive, not a material financial event. The filing has no revenue, earnings, or guidance data, and the stock option is standard for a new officer hire.

Key Facts

  • Septerna granted a non-qualified stock option to purchase 275,000 shares to new CMO Rajiv Patni
  • Grant effective September 8, 2026, under the 2026 Inducement Plan
  • Award is an inducement material to employment per Nasdaq Listing Rule 5635(c)(4)
  • No financial results, guidance, or material business developments disclosed

Financial Impact

275,000-share option grant; no dollar value stated

dilution

Risk Factors

  • Potential dilution from option exercise, though immaterial relative to outstanding shares
  • No revenue or near-term catalysts disclosed in this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3359956

Track record

25 reports on SEPN

Performance horizon

7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +55.96% at T+60 after the Apr 13, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry price pending
  2. Nov 16, 2026today 144 Neutral 2/10 Entry price pending
  3. Nov 12, 20264d ago 144 Neutral 3/10 Entry $42.60 Now $42.60 −0.00% settles Nov 20
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $42.60 −0.00% settles Nov 20
  5. Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $42.60 +1.77% settles Nov 19
  6. Nov 9, 20267d ago Press Release Bearish 5/10 Entry $52.34 Now $42.60 +18.61% settles Nov 17
  7. Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $42.60 −11.03% ▲ +1.42% +2.33% vs SPY
  8. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $42.60 −11.03% ▲ +1.42% +2.33% vs SPY
  9. Sep 10, 20269w ago Press Release Neutral 2/10 Viewing Entry $38.51 to $38.69 Now $42.60 +10.62% ▲ +0.47% +0.69% vs SPY
  10. Sep 3, 202610w ago 3 Neutral 2/10 Entry $36.75 to $39.55 Now $42.60 +15.92% ▲ +7.62% +8.83% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (12h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 10, 2026